Title : Paclitaxel and fisetin loaded RBC-PCL biomimetic nanofor-mulation as advanced chemotherapeutics agent
Abstract:
The development of advanced drug delivery systems tends to have immense potential for improving efficacy and minimizing side effects of cancer therapy. This work is intended to investigate the possibility of targeted drug delivery using red blood cells as biomimetic nanoformulations. To increase the biocompatibility and circulation time in the bloodstream, the nanoformulations were made to resemble the surface characterization of RBCs closely. Our study also explores the synergistic anticancer effects of paclitaxel (PTX) and Fisetin (FIS) encapsulated within biocompatible polymer nanoparticles which is polycaprolactone further enriched by red blood cell membrane. The co-delivery system here aims to capitalize on the individual strengths of PTX, a well-established Taxol, and FIS, a natural flavonoid known for its anti-cancer properties and anti-inflammatory properties. Paclitaxel is known to show certain serious side effects that can be minimized with the help of the anti-inflammatory properties of Fisetin. Physicochemical characterization further confirmed the successful encapsulation, optimal particle size in the nano range, and controlled release kinetics of the nanoparticles. Thus, enhancing the interaction time in the system. In vitro studies demonstrated the enhanced cytotoxic effects of the combination therapy on various cancer cell lines compared to individual drug treatments. The findings from this study underscore the potential of PTX and FIS co-loaded biomimetic nanoparticles as a promising strategy for advanced cancer therapeutics, providing a foundation for further preclinical and clinical investigations. The multifaceted approach here helps enhance therapeutic outcomes and opens new avenues for developing personalized and targeted cancer treatments.
Keywords: Combination Chemotherapy; Biomimetic Nanoparticles; Paclitaxel; Fisetin; Cancer; Red Blood Cell Membrane
